Last reviewed · How we verify
VLP-Polio high dose — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
VLP-Polio high dose (VLP-Polio high dose) — CanSino Biologics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| VLP-Polio high dose TARGET | VLP-Polio high dose | CanSino Biologics Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- VLP-Polio high dose CI watch — RSS
- VLP-Polio high dose CI watch — Atom
- VLP-Polio high dose CI watch — JSON
- VLP-Polio high dose alone — RSS
Cite this brief
Drug Landscape (2026). VLP-Polio high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/vlp-polio-high-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing